Last reviewed · How we verify
NCT04378855: PROPHECY
Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY).
trial testing Questionnaire in Myeloproliferative Neoplasm in 572 participants. Participants enrolled and being followed up; not accepting new ones.
15 November 2023
Quick facts
| Lead sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 572 |
| Start date | 29 May 2020 |
| Primary completion | 15 November 2023 |
| Estimated completion | 15 November 2025 |
| Sites | 25 locations across Italy |
Drugs / interventions tested
- Questionnaire
Conditions studied
- Myeloproliferative Neoplasm — all drugs for Myeloproliferative Neoplasm →
Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto — full company profile →
Who can join
18 and older, any sex, with Myeloproliferative Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will ultimately aim at developing a GIMEMA platform for collecting HRQoL and symptom burden information on Italian patients with Philadelphia chromosome negative MPN. The main objective of the protocol is to improve our understanding of the impact of the disease and various treatments on patients-wellbeing, symptom burden and daily functioning.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Health-related quality of life and symptom profile of patients with <i>BCR::ABL1</i>-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational study.
Caocci G, Costa A, Palandri F, Guglielmelli P, et al · · 2025 · PMID 41473003 · DOI 10.1002/hem3.70274
Verify or expand the search:
- PubMed search for NCT04378855
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Questionnaire
Trials testing the same drug.
- NCT04466371 — Perceptions of Undergraduate Students and Teaching Staff on Online Teaching · suspended
- NCT07089953 — Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits: a Randomiz · NA · not yet recruiting
- NCT07418775 — Tumor Genomics, Individual Risk Factors, and External Drivers of Health on Health Outcomes for Patients With Meningioma · not yet recruiting
- NCT07226804 — Nanosecond Pulsed Field Ablation in the Management of Benign Thyroid Nodules · not yet recruiting
- NCT07532954 — The Impact Of A Patient Support Community On Patients With Neuroendocrine Cervical Cancer: NECC Peer Support · recruiting
Other recruiting trials for Myeloproliferative Neoplasm
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT06468033 — P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk · Phase 3 · recruiting
- NCT06815003 — Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Di · Phase 2 · recruiting
- NCT05745285 — Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care · NA · recruiting
- NCT06553638 — Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloprolif · active not recruiting
Other Gruppo Italiano Malattie EMatologiche dell'Adulto trials
Trials by the same sponsor.
- NCT07356960 — Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world · not yet recruiting
- NCT07158294 — Identification of BCR::ABL1 Mutations by Digital PCR in CML · NA · not yet recruiting
- NCT07249606 — Momelotinib Effectiveness in Myelofibrosis · not yet recruiting
- NCT06880601 — Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma · Phase 2 · not yet recruiting
- NCT06657846 — HRQoL and Financial Toxicity in Patients With VEXAS Syndrome · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04378855 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gruppo Italiano Malattie EMatologiche dell'Adulto
- Last refreshed: 23 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04378855.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing